Rat mesothelioma cell proliferation requires p38δ mitogen activated protein kinase and C/EBP-α

Lung Cancer

Volumn 73, Issue 2, 2011, Pages 166-170

  Zhong, Jun ^a   Lardinois, Didier ^a   Szilard, John ^b   Tamm, Michael ^a   Roth, Michael ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

CCAAT enhancer binding protein; Mesothelioma; Mitogen activated protein kinase; P38; Proliferation; Rat model

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 13; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 3; PLATELET DERIVED GROWTH FACTOR BB; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSOL; DOWN REGULATION; IMMUNOBLOTTING; NONHUMAN; NUCLEUS ACCUMBENS; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; GENE EXPRESSION; MESOTHELIOMA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGENS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; PLEURAL NEOPLASMS; PROTEIN ISOFORMS; RATS; RATS, INBRED F344;

EID: 79960060053     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.12.003     Document Type: Article

References (46)

1. Pasetto R., Comba P., Marconi A. Mesothelioma associated with environmental exposures. Med Lav 2005, 96:330-337.
2. Robinson B.W., Musk A.W., Lake R.A. Malignant mesothelioma. Lancet 2005, 366:397-408.
3. Okubo K., Sonobe M., Fujinaga T., Shoji T., Sakai H., Miyahara R., et al. Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma. Gen Thorac Cardiovasc Surg 2009, 57:585-590.
4. Neragi-Miandoab S. Multimodality approach in management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2006, 29:14-19.
5. Price B., Ware A. Mesothelioma trends in the United States: an update based on surveillance. Epidemiology, and end results program data for 1973 through 2003. Am J Epidemiol 2004, 159:107-112.
6. Langard S. Nordic experience: expected decline in the incidence of mesotheliomas resulting from ceased exposure?. Med Lav 2005, 96:304-311.
7. Donaldson K., Murphy F.A., Duffin R., Poland C.A. Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma. Part Fibre Toxicol 2010, 7:5.
8. Ryman-Rasmussen J.P., Cesta M.F., Brody A.R., Shipley-Phillips J.K., Everitt J.I., Tewksbury E.W., et al. Inhaled carbon nanotubes reach the subpleural tissue in mice. Nat Nanotechnol 2009, 4:747-751.
9. Brunner T.J., Wick P., Manser P., Spohn P., Grass R.N., Limbach L.K., et al. In vitro cytotoxicity of oxide nanoparticles: comparison to asbestos, silica, and the effect of particle solubility. Environ Sci Technol 2006, 40:4374-4381.
10. Swain W.A., O'Byrne K.J., Faux S.P. Activation of p38 MAP kinase by asbestos in rat mesothelial cells is mediated by oxidative stress. Am J Physiol Lung Cell Mol Physiol 2004, 286. L859-5.
11. Fung H., Quinlan T.R., Janssen Y.M., Timblin C.R., Marsh J.P., Heintz N.H., et al. Inhibition of protein kinase C prevents asbestos-induced c-fos and c-jun proto-oncogene expression in mesothelial cells. Cancer Res 1997, 57:3101-3105.
12. Walker C., Bermudez E., Stewart W., Bonner J., Molloy C.J., Everitt J. Characterization of platelet-derived growth factor and platelet-derived growth factor receptor expression in asbestos-induced rat mesothelioma. Cancer Res 1992, 52:301-306.
13. Langerak A.W., De Laat P.A., Van Der Linden-Van Beurden C.A., Delahaye M., Van Der Kwast T.H., Hoogsteden H.C., et al. Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. J Pathol 1996, 178:151-160.
14. Kuwahara M., Takeda M., Takeuchi Y., Kuwahara M., Harada T., Maita K. Transforming growth factor beta production by spontaneous malignant mesothelioma cell lines derived from Fisher 344 rats. Virchows Arch 2001, 438:492-497.
15. Kim Y., Ton T.V., DeAngelo A.B., Morgan K., Devereux T.R., Anna C., et al. Major carcinogenic pathways identified by gene expression analysis of peritoneal mesotheliomas following chemical treatment in F344 rats. Toxicol Appl Pharmacol 2006, 214:144-151.
16. Wakchoure S., Merrell M.A., Aldrich W., Millender-Swain T., Harris K.W., Triozzi P., et al. Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res 2006, 12:2862-2868.
17. Patel D.N., King C.A., Bailey S.R., Holt J.W., Venkatachalam K., Agrawal A., et al. Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation. J Biol Chem 2007, 282:27229-27238.
18. Zhong J., Gencay M.M., Bubendorf L., Burgess J.K., Parson H., Robinson B.W., et al. ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells. J Cell Physiol 2006, 207:540-552.
19. Roth M., Zhong J., Tamm M., Szilard J. Mesothelioma cells escape heat stress by upregulating Hsp40/Hsp70 expression via mitogen-activated protein kinases. J Biomed Biotechnol 2009, 2009:451084.
20. Vintman L., Nielsen S., Berner A., Reich R., Davidson B. Mitogen-activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells. Cancer 2005, 103:2427-2433.
21. Loesch M., Chen G. The p38 MAPK stress pathway as a tumor suppressor or more?. Front Biosci 2008, 13:3581-3593.
22. Feng Y., Wen J., Chang C.C. p38 Mitogen-activated protein kinase and hematologic malignancies. Arch Pathol Lab Med 2009, 133:1850-1856.
23. Wang L.H., Yang X.Y., Zhang X., Farrar W.L. Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARgamma cross talk with NF-kappaB and C/EBP. Blood 2007, 110:4373-4384.
24. Nagy N., Shiroto K., Malik G., Huang C.K., Gaestel M., Abdellatif M., et al. Ischemic preconditioning involves dual cardio-protective axes with p38MAPK as upstream target. J Mol Cell Cardiol 2007, 42:981-990.
25. Lardinois D., Jung F.J., Opitz I., Rentsch K., Latkoczy C., Vuong V., et al. Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma. J Thorac Cardiovasc Surg 2006, 131:697-703.
26. Hostettler K.E., Roth M., Burgess J.K., Johnson P.R., Glanville A.R., Tamm M., et al. Cyclosporine A mediates fibroproliferation through epithelial cells. Transplant 2004, 77:1886-1893.
27. Kim N., Choi S., Lim C., Lee H., Oh J. Albumin mediates PPAR-gamma or C/EBP-alpha-induced phenotypic changes in pancreatic stellate cells. Biochem Biophys Res Commun 2010, 391:640-644.
28. Costa D.B., Dayaram T., D'Alo F., Wouters B.J., Tenen D.G., Meyerson M., et al. Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590. Lung Cancer 2007, 56:97-103.
29. Seagroves T.N., Lydon J.P., Hovey R.C., Vonderhaar B.K., Rosen J.M. C/EBPbeta (CCAAT/enhancer binding protein) controls cell fate determination during mammary gland development. Mol Endocrinol 2000, 14:359-368.
30. Grimm S.L., Contreras A., Barcellos-Hoff M.H., Rosen J.M. Cell cycle defects contribute to a block in hormone-induced mammary gland proliferation in CCAAT/enhancer-binding protein (C/EBPbeta)-null mice. J Biol Chem 2005, 280:36301-36309.
31. Grimm S.L., Rosen J.M. The role of C/EBPbeta in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 2003, 8:191-204.
32. Hu M.C., Wang Y.P., Mikhail A., Qiu W.R., Tan T.H. Murine p38-delta mitogen-activated protein kinase, a developmentally regulated protein kinase that is activated by stress and proinflammatory cytokines. J Biol Chem 1999, 274:7095-7102.
33. Efimova T., Deucher A., Kuroki T., Ohba M., Eckert R.L. Novel protein kinase C isoforms regulate human keratinocyte differentiation by activating a p38 delta mitogen-activated protein kinase cascade that targets CCAAT/enhancer-binding protein alpha. J Biol Chem 2002, 277:31753-31760.
34. Adhikary G., Chew Y.C., Reece E.A., Eckert R.L. PKC-delta and -eta, MEKK-1, MEK-6, MEK-3, and p38-delta Are Essential Mediators of the Response of Normal Human Epidermal Keratinocytes to Differentiating Agents. J Invest Dermatol 2010, [Epub ahead of print].
35. Sundaramurthy P., Gakkhar S., Sowdhamini R. Analysis of the impact of ERK5, JNK, and P38 kinase cascades on each other: a systems approach. Bioinformation 2009, 3:244-249.
36. Melo M., Gerbase M.W., Curran J., Pache J.C. Phosphorylated extracellular signal-regulated kinases are significantly increased in malignant mesothelioma. J Histochem Cytochem 2006, 54:855-861.
37. Eckert R.L., Efimova T., Balasubramanian S., Crish J.F., Bone F., Dashti S. p38 Mitogen-activated protein kinases on the body surface-a function for p38 delta. J Invest Dermatol 2003, 120:823-828.
38. Efimova T., Broome A.M., Eckert R.L. A regulatory role for p38 delta MAPK in keratinocyte differentiation. Evidence for p38 delta-ERK1/2 complex formation. J Biol Chem 2003, 278:34277-34285.
39. Franco-Montoya M.L., Bourbon J.R., Durrmeyer X., Lorotte S., Jarreau P.H., Delacourt C. Pulmonary effects of keratinocyte growth factor in newborn rats exposed to hyperoxia. Am J Physiol Lung Cell Mol Physiol 2009, 297:L965-L976.
40. Kamp D.W., Weitzman S.A. The molecular basis of asbestos induced lung injury. Thorax 1999, 54:638-652.
41. Hicks J. Biologic, cytogenetic, and molecular factors in mesothelial proliferations. Ultrastruct Pathol 2006, 30:19-30.
42. Keum Y.S., Yu S., Chang P.P., Yuan X., Kim J.H., Xu C., et al. Mechanism of action of sulforaphane: inhibition of p38 mitogen-activated protein kinase isoforms contributing to the induction of antioxidant response element-mediated heme oxygenase-1 in human hepatoma HepG2 cells. Cancer Res 2006, 66:8804-8813.
43. Calkhoven C.F., Snippe L., Ab G. Differential stimulation by CCAAT/enhancer-binding protein alpha isoforms of the estrogen-activated promoter of the very-low-density apolipoprotein II gene. Eur J Biochem 1997, 249:113-120.
44. Müller C., Bremer A., Schreiber S., Eichwald S., Calkhoven C.F. Nucleolar retention of a translational C/EBPalpha isoform stimulates rDNA transcription and cell size. EMBO J 2010, 29:897-909.
45. Nilsonne G., Olm E., Szulkin A., Mundt F., Stein A., Kocic B., et al. Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure. J Exp Clin Cancer Res 2009, 28:92.
46. Hjerpe A., Dobra K. Malignant mesothelioma-a connective tissue tumor with proteoglycan-dependent differentiation. Connect Tissue Res 2008, 49:249-251.